{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:25:50Z","timestamp":1773865550457,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The objective of this prospective study was to investigate the morphological changes of myopic choroidal neovascularization (mCNV) after treatment with anti-vascular endothelial growth factor and to identify potential features predictive of the final BCVA. OCT and OCTA features were evaluated at baseline and at 1, 6 and 12\u00a0months. Parameters investigated were the maturity pattern, presence of mCNV OCT activity signs, subretinal fibrosis and mCNV area. Forty patients (41 eyes) were included in the study. At the final visit, after a mean of 3.1\u2009\u00b1\u20091.4 injections, BCVA had improved significantly (p\u2009=\u20090.009) and subretinal hyperreflective exudation, subretinal fluid and intraretinal cysts nearly disappeared at 12\u00a0months. At baseline, 20 eyes had an immature CNV that were smaller, required less injections (2.5\u2009\u00b1\u20091.2 vs 3.8\u2009\u00b1\u20091.4, p\u2009=\u20090.002), they completely regressed in seven eyes and achieved a better BCVA (0.14\u2009\u00b1\u20090.15 vs 0.40\u2009\u00b1\u20090.26 logMAR, p\u2009&lt;\u20090.001) when compared to mature CNV. Subretinal fibrosis developed in 19 eyes (46.3%) with lower final BCVA than eyes without fibrosis (0.19\u2009\u00b1\u20090.24 vs 0.38\u2009\u00b1\u20090.22 logMAR, p\u2009=\u20090.012). Baseline immature pattern (p\u2009=\u20090.005) and baseline BCVA (p\u2009&lt;\u20090.001) were predictive of final BCVA. Multimodal imaging is useful to define mCNV changes during treatment. OCTA provides prognostic information which cannot achieved by other imaging techniques.<\/jats:p>","DOI":"10.1038\/s41598-022-14287-7","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T14:09:08Z","timestamp":1655820548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Morphological parameters of myopic choroidal neovascularization as predictive factors of anti-VEGF treatment response"],"prefix":"10.1038","volume":"12","author":[{"given":"Niccol\u00f2","family":"Castellino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Battaglia Parodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario Damiano","family":"Toro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Fallico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenza","family":"Bonfiglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agatino Davide","family":"Maugeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresio","family":"Avitabile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Longo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"14287_CR1","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.ophtha.2015.03.018","volume":"122","author":"KM Williams","year":"2015","unstructured":"Williams, K. M. et al. Increasing prevalence of myopia in Europe and the impact of education. Ophthalmology 122, 1489\u20131497 (2015).","journal-title":"Ophthalmology"},{"key":"14287_CR2","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ajo.2012.02.027","volume":"154","author":"C-W Pan","year":"2012","unstructured":"Pan, C.-W. et al. Variation in prevalence of myopia between generations of migrant Indians living in Singapore. Am. J. Ophthalmol. 154, 376-381.e1 (2012).","journal-title":"Am. J. Ophthalmol."},{"key":"14287_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","volume":"157","author":"TY Wong","year":"2014","unstructured":"Wong, T. Y., Ferreira, A., Hughes, R., Carter, G. & Mitchell, P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: An evidence-based systematic review. Am. J. Ophthalmol. 157, 9-25.e12 (2014).","journal-title":"Am. J. Ophthalmol."},{"key":"14287_CR4","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0161-6420(83)80018-9","volume":"90","author":"GR Hampton","year":"1983","unstructured":"Hampton, G. R., Kohen, D. & Bird, A. C. Visual prognosis of disciform degeneration in myopia. Ophthalmology 90, 923\u2013926 (1983).","journal-title":"Ophthalmology"},{"key":"14287_CR5","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1097\/IAE.0b013e318174417a","volume":"28","author":"Y Ikuno","year":"2008","unstructured":"Ikuno, Y. et al. Lacquer crack formation and choroidal neovascularization in pathologic myopia. Retina 28, 1124\u20131131 (2008).","journal-title":"Retina"},{"key":"14287_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.preteyeres.2012.04.001","volume":"31","author":"K Neelam","year":"2012","unstructured":"Neelam, K., Cheung, C. M. G., Ohno-Matsui, K., Lai, T. Y. Y. & Wong, T. Y. Choroidal neovascularization in pathological myopia. Prog. Retin. Eye Res. 31, 495\u2013525 (2012).","journal-title":"Prog. Retin. Eye Res."},{"key":"14287_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/bjophthalmol-2016-309162","volume":"101","author":"L Querques","year":"2017","unstructured":"Querques, L. et al. Optical coherence tomography angiography of myopic choroidal neovascularisation. Br. J. Ophthalmol. 101, 609\u2013615 (2017).","journal-title":"Br. J. Ophthalmol."},{"key":"14287_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/IAE.0000000000002388","volume":"40","author":"P Milani","year":"2020","unstructured":"Milani, P. et al. Optical coherence tomography angiography features of subretinal fibrosis after myopic neovascularization. Retina 40, 249\u2013256 (2020).","journal-title":"Retina"},{"key":"14287_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00417-018-04205-x","volume":"257","author":"SY Cohen","year":"2019","unstructured":"Cohen, S. Y. et al. Vascular remodeling of choroidal neovascularization in older myopic patients treated with ranibizumab. Graefe\u2019s Arch. Clin. Exp. Ophthalmol. 257, 485\u2013493 (2019).","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"14287_CR10","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1097\/IAE.0000000000002005","volume":"39","author":"Y Cheng","year":"2019","unstructured":"Cheng, Y., Li, Y., Huang, X. & Qu, Y. Application of optical coherence tomography angiography to assess anti-vascular endothelial growth factor therapy in myopic choroidal neovascularization. Retina 39, 712\u2013718 (2019).","journal-title":"Retina"},{"key":"14287_CR11","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","volume":"121","author":"S Wolf","year":"2014","unstructured":"Wolf, S. et al. RADIANCE: A randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 121, 682-692.e2 (2014).","journal-title":"Ophthalmology"},{"key":"14287_CR12","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","volume":"122","author":"Y Ikuno","year":"2015","unstructured":"Ikuno, Y. et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: The MYRROR study. Ophthalmology 122, 1220\u20131227 (2015).","journal-title":"Ophthalmology"},{"key":"14287_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00417-004-0960-5","volume":"243","author":"K Hayashi","year":"2005","unstructured":"Hayashi, K. et al. Characteristics of patients with a favorable natural course of myopic choroidal neovascularization. Graefe\u2019s Arch. Clin. Exp. Ophthalmol. 243, 13\u201319 (2005).","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"14287_CR14","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/eye.2012.75","volume":"26","author":"U Introini","year":"2012","unstructured":"Introini, U. et al. Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularization. Eye 26, 976\u2013982 (2012).","journal-title":"Eye"},{"key":"14287_CR15","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.ajo.2015.07.004","volume":"160","author":"E Bruy\u00e8re","year":"2015","unstructured":"Bruy\u00e8re, E. et al. Spectral-domain optical coherence tomography of subretinal hyperreflective exudation in myopic choroidal neovascularization. Am. J. Ophthalmol. 160, 749\u2013758 (2015).","journal-title":"Am. J. Ophthalmol."},{"key":"14287_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/IAE.0000000000000684","volume":"36","author":"M Battaglia Parodi","year":"2016","unstructured":"Battaglia Parodi, M., Iacono, P. & Bandello, F. Correspondence of leakage on fluorescein angiography and optical coherence tomography parameters in diagnosis and monitoring of myopic choroidal neovascularization treated with bevacizumab. Retina 36, 104\u2013109 (2016).","journal-title":"Retina"},{"key":"14287_CR17","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1097\/IAE.0000000000002650","volume":"40","author":"S Li","year":"2020","unstructured":"Li, S. et al. Assessing the activity of myopic choroidal neovascularization: Comparison between optical coherence tomography angiography and dye angiography. Retina 40, 1757\u20131764 (2020).","journal-title":"Retina"},{"key":"14287_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ajo.2016.03.009","volume":"165","author":"M Miyata","year":"2016","unstructured":"Miyata, M. et al. Detection of myopic choroidal neovascularization using optical coherence tomography angiography. Am. J. Ophthalmol. 165, 108\u2013114 (2016).","journal-title":"Am. J. Ophthalmol."},{"key":"14287_CR19","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1097\/IAE.0000000000001436","volume":"37","author":"P Iacono","year":"2017","unstructured":"Iacono, P. et al. Factors influencing visual acuity in patients receiving anti-vascular endothelial growth factor for myopic choroidal neovascularization. Retina 37, 1931\u20131941 (2017).","journal-title":"Retina"},{"key":"14287_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100906","volume":"82","author":"PS Mettu","year":"2021","unstructured":"Mettu, P. S., Allingham, M. J. & Cousins, S. W. Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Prog. Retin. Eye Res. 82, 100906 (2021).","journal-title":"Prog. Retin. Eye Res."},{"key":"14287_CR21","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1097\/IAE.0000000000001043","volume":"36","author":"SJ Ahn","year":"2016","unstructured":"Ahn, S. J., Park, K. H. & Woo, S. J. Subretinal fibrosis after antivascular endothelial growth factor therapy in eyes with myopic choroidal neovascularization. Retina 36, 2140\u20132149 (2016).","journal-title":"Retina"},{"key":"14287_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1136\/bjophthalmol-2019-315763","volume":"105","author":"H Xiao","year":"2021","unstructured":"Xiao, H. et al. Risk factors for subretinal fibrosis after anti-VEGF treatment of myopic choroidal neovascularisation. Br. J. Ophthalmol. 105, 103\u2013108 (2021).","journal-title":"Br. J. Ophthalmol."},{"key":"14287_CR23","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1167\/iovs.17-23640","volume":"59","author":"M Battaglia Parodi","year":"2018","unstructured":"Battaglia Parodi, M., Iacono, P., Romano, F. & Bandello, F. Fluorescein leakage and optical coherence tomography features of choroidal neovascularization secondary to pathologic myopia. Invest. Ophthalmol. Vis. Sci. 59, 3175\u20133180 (2018).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"14287_CR24","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/IAE.0000000000001236","volume":"37","author":"L Ceklic","year":"2017","unstructured":"Ceklic, L., Munk, M. R., Wolf-Schnurrbusch, U., Gekkieva, M. & Wolf, S. Visual acuity outcomes of ranibizumab treatment in pathologic myopic eyes with macular retinoschisis and choroidal neovascularization. Retina 37, 687\u2013693 (2017).","journal-title":"Retina"},{"key":"14287_CR25","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1097\/IAE.0000000000001456","volume":"37","author":"E Bruy\u00e8re","year":"2017","unstructured":"Bruy\u00e8re, E. et al. Neovascularization secondary to high myopia imaged by optical coherence tomography angiography. Retina 37, 2095\u20132101 (2017).","journal-title":"Retina"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14287-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14287-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14287-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T06:02:07Z","timestamp":1669356127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14287-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["14287"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-14287-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"11 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10435"}}